PFSCF News Alert Prometic Life Scienc (PFSCF) 1.5900 09/26/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 26, 2014 at 11:06 AM

Prometic Life Scienc (PFSCF) 1.5900 $PFSCF

ProMetic to Be Added to S&P/TSX SmallCap Index
Marketwire - Tue Sep 16, 6:01AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation"

announced today that it will be added to the S&P/TSX SmallCap Index ("Index"

, effective after the close of trading on Friday, September 19, 2014, as the result of the annual review of the Index.

Chemotherapy Induced Anemia Therapeutics Pipeline Review 2014 - 9 Companies & 11 Drug Profiles
M2 - Wed Sep 10, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqbww2/chemotherapy) has announced the addition of the "Chemotherapy Induced Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Eli Lilly and Company - 3SBio Inc. - ProMetic Life Sciences Inc. - Avesthagen Limited - Therapure Biopharma Inc. - Tarix Pharmaceuticals LTD. - Aprogen, Inc. - Tolero Pharmaceuticals, Inc. - SBI Pharmaceuticals Co., Ltd. Drug Profiles - epoetin alfa - PBI-1402 - LY-2787106 - aminolevulinic acid hydrochloride - NuPIAO - darbepoetin alfa - PanCyte - PBI-4494 - TBI-304 - darbepoetin alfa - TP-0413 For more information visit http://www.researchandmarkets.com/research/tq...emotherapy

Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ProMetic Reports Successful PBI-4050 Pre-IND Meeting with the FDA
Marketwire - Wed Sep 03, 5:31AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"

announced today it had a successful Pre-Investigational New Drug ("Pre-IND) meeting with the US Food and Drug Administration ("FDA"

for its anti-fibrotic, lead drug candidate, PBI-4050.

ProMetic Reports its Second Quarter 2014 Highlights and Financial Results
Marketwire - Thu Aug 14, 3:02PM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation"

today reported revenues of $4.4 million and a net profit of $23.4 million for the second quarter ended June 30, 2014 resulting from the recognition of a gain on revaluation of the equity investment of ProMetic's equity interest in NantPro.

ProMetic to Report its Second Quarter 2014 Financial Results and Hold Conference Call / Webcast
Marketwire - Mon Aug 11, 11:35AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"

today announced that it will report its financial results for the second quarter ended June 30, 2014 on Thursday August 14, 2014 after market hours.

ProMetic Secures $20 Million Follow-on Investment from Thomvest Seed Capital Inc.
Marketwire - Fri Aug 01, 7:18AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation"

announced today that it has secured a follow-on investment from Thomvest Seed Capital Inc. ("Thomvest"

, the Toronto-based investment vehicle of Peter J. Thomson, consisting of a $20 million Loan. As partial consideration for the Loan, ProMetic has granted Thomvest 16,723,807 warrants with an exercise price of $1.87 per common share, a premium of 52% to yesterday's closing share price.

ProMetic Enters Into New Product Program With an Existing Multinational Client
Marketwire - Thu Jul 24, 7:40AM CDT
July 24, 2014 - ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"

announced today the signing of an agreement (the "Agreement"

by ProMetic's UK subsidiary, ProMetic Biosciences Ltd ("PBL"

, with one of its existing multinational clients, a global leader in the biotherapeutics industry.

ProMetic to Commercially Launch Fibrinogen in the Fourth Quarter of 2014
Marketwire - Thu Jul 10, 7:09AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"

announced today that it will launch fibrinogen for commercial sales during the fourth quarter of 2014 after its successful scale-up at its Laval based plasma purification facility, ProMetic BioProduction Inc. ("PBP"

. This follows the previously disclosed proteins already scheduled for production at PBP, namely plasminogen, IVIG and Alpha-1 Antitrypsin.

ProMetic Successfully Completes its PBI-4050 Phase I Clinical Trial
Marketwire - Wed Jun 18, 5:01AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation"

reported today that it has successfully completed its PBI-4050 Phase I clinical trial in 40 healthy volunteers. ProMetic's PBI-4050 was found to be safe and very well tolerated without any serious adverse events reported in any of the 5 cohorts tested.

ProMetic Reports Successful Pre-IND Meeting with the FDA
Marketwire - Wed Apr 02, 6:02AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"

announced today that it had a successful Pre-Investigational New Drug ("Pre-IND) meeting with the US Food and Drug Administration ("FDA"

for a plasma-derived biopharmaceutical currently under development under the NantPro, LLC joint venture.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

1M+ California Homes Face Extreme Wildfire Risk Revealed

Wildfire Risk in California: A Growing Alarm If there's one thing that's become a bitter truth over the years, it's that California and wildfires are inseparably linked, like mayo on a greasy diner BLT—except way worse for the gut. The latest round of data from Guidewire HazardHub is practically sounding the alarm bells louder than ever. Over a million homes in...

Spot the Signs: Early Gum Disease Insights from Experts

Why Early Detection of Gum Disease Matters Let's dive right into the crux of things. Gum disease, that sneaky antagonist of oral health, starts unassumingly. You brush, you floss, but those gums might still bleed—ever noticed? Dr. Marian Burgard of Fairport Family Dental has a thing or two to say about this, enlightening us through an insightful piece by HelloNation....

Everpure Surges into the S&P 500: A Milestone Move

Big Leagues Beckon: Everpure Enters the S&P 500 Another day, another dollar, but today ain't just any day for Everpure. They’re stepping up from the minor leagues and grabbing their spot in the illustrious S&P 500 lineup. We're talking about a milestone that every company dreams of, but few achieve—this ain't your regular Tuesday headline. Stock Market's Stamp of...

Big Wins at Americas Cardroom's $15M Venom Series

High Stakes and Huge Paydays: The Venom Breakdown Alright, folks, here's a tale of how the cards fell in one of the most electrifying poker standoffs at Americas Cardroom. With prize pools clocking in at a staggering $15.095 million, the Dual Mystery Bounty Venoms really stacked the chips high. From the gritty, bustling halls of the internet to the proverbial green-felt...

MADD, Uber Rally at Capital Invitational for Safe Choices

Driving Change at the Capital Invitational Let's talk about a powerhouse collaboration aiming to do more than just thrill basketball fans. We're looking at MADD Sports, Uber, and the Capital Invitational joining forces at The St. James in Springfield, Virginia, on December 10, 2026. This is not your average sporting event; it's a gathering with a bigger purpose. The...

Innventure Faces Major Lawsuit Amidst Market Turmoil

The Plot Thickens with Innventure's DarkNX Project Buckle up, fellow market sling-riders; the Innventure tale is a rocky one for the books. Imagine this: You’ve plunked down your hard-earned cash on Innventure Inc. (NASDAQ: INV), lured by their glowing pronouncements about a supposed golden egg project, the Accelsius DarkNX data-center deal. A big talk about...

Illinois' Legal Tangle: Feds Under Fire?

What a tangled web Illinois lawmakers have woven this time. They've gone and cooked up a pair of laws with a real knack for attracting attention—specifically from the folks over at the National Police Association (NPA). These aren’t your run-of-the-mill rules; they feel more like a blueprint for putting federal officers through the legal wringer and turning courtroom...

AllyGPO Shines as Top Innovator in Health Tech

Innovative Excellence in Healthcare Tech It's not every day you see a specialty group purchasing organization like AllyGPO snagging a spot on Fast Company's esteemed list of Best Workplaces for Innovators. Making it into the top half at number 40 in 2026, it’s a testament to a company really leaning into employee-driven innovation. And, buddy, this ain't just corporate...

Austin PostalAnnex Changes Hands After 19 Years

A Seamless Transition in Austin's PostalAnnex Legacy You know when a business digs its roots deep, becoming more than just a place but a part of the community fabric? That's what’s playing out at the PostalAnnex on W Parmer Lane, Austin. After nearly two decades, this battered yet steadfast hub of office and shipping services is swapping hands, all in the name of...

Nashville Benefit Concert Supports Animal Rescue Mission

Country Tunes and Compassion Unite for Rescue Efforts There's something electric about a community banding together, especially when it's through the warmth of country music and the noble mission of animal rescue. Animal Rescue Corps (ARC), meeting ground for art and heart, is turning the Nashville Palace into a sanctuary not just for music, but for hope. They've got...